TCR2 Therapeutics Inc. (TCRR): Price and Financial Metrics
GET POWR RATINGS... FREE!
TCRR Stock Price Chart Interactive Chart >
TCRR Price/Volume Stats
| Current price | $2.30 | 52-week high | $19.85 |
| Prev. close | $2.19 | 52-week low | $2.07 |
| Day low | $2.15 | Volume | 289,500 |
| Day high | $2.31 | Avg. volume | 579,837 |
| 50-day MA | $2.47 | Dividend yield | N/A |
| 200-day MA | $5.86 | Market Cap | 88.66M |
TCR2 Therapeutics Inc. (TCRR) Company Bio
TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.
Latest TCRR News From Around the Web
Below are the latest news stories about Tcr2 Therapeutics Inc that investors may wish to consider to help them evaluate TCRR as an investment opportunity.
Tcr2 Therapeutics (TCRR) presents Interim Data from Ongoing Gavo-cel Phase 1/2 Clinical TrialThe following slide deck was published by TCR2 Therapeutics Inc. in conjunction with this event.... |
TCR2 Therapeutics (TCRR) Investor PresentationThe following slide deck was published by TCR2 Therapeutics Inc. in conjunction with this event.... |
TCRR Price Returns
| 1-mo | 7.98% |
| 3-mo | -15.13% |
| 6-mo | -55.34% |
| 1-year | -87.99% |
| 3-year | -84.25% |
| 5-year | N/A |
| YTD | -50.64% |
| 2021 | -84.93% |
| 2020 | 116.60% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...